Audited Full Year Fiscal 2025 Results

Summary by AI BETAClose X

Renalytix plc reported its audited fiscal year 2025 results, with total revenues up 30% to $3.0 million from $2.3 million in FY24. Testing revenue increased to $2.7 million, while pharmaceutical revenues grew by 200% to $0.3 million. The gross margin for the year was 40%, a significant increase from 9% in FY24. Administrative expenses totaled $18.4 million, down from $30.7 million. The company recognized $1.4 million in R&D tax credits. A loss of $0.6 million was recorded to adjust the VericiDx investment to fair value. A post-year-end fundraise in September 2025 raised approximately $9.0 million. The Group had cash on hand of $3.6 million at year end. Outstanding long-term debt was £3.1 million as of October 2025 after the conversion of $4 million of convertible debt.

Disclaimer*

UK 100

Latest directors dealings